Reaction Details Report a problem with these data
Target
Kallikrein-1
Ligand
BDBM247411
Substrate
n/a
Meas. Tech.
ChEMBL_2155711 (CHEMBL5040371)
Ki
>11000±n/a nM
Citation
Dilger, AK; Pabbisetty, KB; Corte, JR; De Lucca, I; Fang, T; Yang, W; Pinto, DJP; Wang, Y; Zhu, Y; Mathur, A; Li, J; Hou, X; Smith, D; Sun, D; Zhang, H; Krishnananthan, S; Wu, DR; Myers, JE; Sheriff, S; Rossi, KA; Chacko, S; Zheng, JJ; Galella, MA; Ziemba, T; Dierks, EA; Bozarth, JM; Wu, Y; Crain, E; Wong, PC; Luettgen, JM; Wexler, RR; Ewing, WR Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy. J Med Chem 65:1770-1785 (2022) [PubMed] Article
More Info.:
Target
Name:
Kallikrein-1
Synonyms:
KLK1 | KLK1_HUMAN | Kallikrein 1 | Kallikrein-1 | Kidney/pancreas/salivary gland kallikrein | Tissue kallikrein
Type:
Enzyme
Mol. Mass.:
28874.69
Organism:
Homo sapiens (Human)
Description:
P06870
Residue:
262
Sequence:
MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS